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Abstract
Background: During the 2009 influenza A/H1N1v pandemic, children were identified as a specific “at risk” group.
We conducted a multicentric study to describe pattern of influenza A/H1N1v infection among hospitalized children
in Brussels, Belgium.
Methods: From July 1, 2009, to January 31, 2010, we collected epidemiological and clinical data of all proven
(positive H1N1v PCR) and probable (positive influenza A antigen or culture) pediatric cases of influenza A/H1N1v
infections, hospitalized in four tertiary centers.
Results: During the epidemic period, an excess of 18% of pediatric outpatients and emergency department visits
was registered. 215 children were hospitalized with proven/probable influenza A/H1N1v infection. Median age was
31 months. 47% had ≥ 1 comorbid conditions. Febrile respiratory illness was the most common presentation. 36%
presented with initial gastrointestinal symptoms and 10% with neurological manifestations. 34% had pneumonia.
Only 24% of the patients received oseltamivir but 57% received antibiotics. 10% of children were admitted to PICU,
seven of whom with ARDS. Case fatality-rate was 5/215 (2%), concerning only children suffering from chronic
neurological disorders. Children over 2 years of age showed a higher propensity to be admitted to PICU (16% vs
1%, p = 0.002) and a higher mortality rate (4% vs 0%, p = 0.06). Infants less than 3 months old showed a milder
course of infection, with few respiratory and neurological complications.
Conclusion: Although influenza A/H1N1v infections were generally self-limited, pediatric burden of disease was
significant. Compared to other countries experiencing different health care systems, our Belgian cohort was
younger and received less frequently antiviral therapy; disease course and mortality were however similar.
Background
On March 2009, in Mexico, a novel recombinant influ-
enza strain (A/H1N1v) of swine origin was discovered
as an infective agent in humans [1]. This new virus
spread rapidly, first to USA and Canada, then all over
the world, causing the “new 2009 influenza A/H1N1v
pandemic” [2]. Worldwide, the burden of disease was
significant and subsequent efforts from health care sys-
tems were required to face an overload of patient’sc o n -
sultations as well as to implement vaccination and
surveillance programs. Although consequences of the
pandemic were less dramatic than initially feared, the
World Health Organization (WHO) estimated that the
virus was responsible of at least 17700 deaths worldwide
and the Centers for Disease Control and Prevention
(CDC) reported 59 millions infected people in the USA
[3-5]).
During this A/H1N1v flu wave, children and young
adults were identified as a particular risk group. They
presented a higher attack rate than older adults [6]
and a greater mortality rate than previously observed
with classical seasonal flu [7,8]. Several reports on
influenza A/H1N1v in pediatric settings have now
been published [9-12], but information on clinical
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dren remains limited [13-15]. However, these data
could be of the great interest to guide future recom-
mendations for vaccination and antiviral therapy dur-
ing forecoming flu seasons.
Belgium experienced the influenza A/H1N1v epi-
demic from July 2009 to January 2010. Pandemic vac-
cine (adjuvanted Pandemrix
®) was only available after
the peak occurred in October and was given with
priority to risk groups (defined as health care workers,
pregnant women and chronically ill patients) [16].
According to our national surveillance system, around
214531 people were infected, 733000 could benefit
from vaccination and 19 deaths were attributable to
the virus [17].
In this context, we conducted a multicenter study ana-
lyzing influenza A/H1N1v pediatric cases hospitalized in
four tertiary medical centers of Brussels, Belgium. Our
study aimed to offer a comprehensive description of
influenza A/H1N1v infection in children, in the light of
other recently published data from countries experien-
cing different health care systems [9-12].
Methods
Study design and population
In collaboration with infection control units and micro-
biology laboratories, we prospectively registered all pro-
ven and probable pediatric cases of influenza A/H1N1v
infections hospitalized in four tertiary facilities of Brus-
sels (Hôpital Universitaire des Enfants Reine Fabiola,
Universitair Ziekenhuis of Brussels, Cliniques Universi-
taires Saint-Luc and Hôpital Saint-Pierre). These facil-
ities totalize 406 pediatric beds, representing 80% of the
total pediatric beds available in Brussels (about 1 million
inhabitants in 2009). Moreover, three of the hospitals
have a Pediatric Intensive Care Unit (PICU) where criti-
cally-ill children from other hospitals of Brussels and
the surrounding areas are referred to (in total 32 PICU
beds available).
The study period extended from July 1, 2009, to Janu-
ary 31, 2010. Children were included if they were aged
from 0 to 18 years, presented with clinical symptoms
compatible with influenza (fever and/or respiratory
signs/symptoms) and had either positive PCR results for
influenza A/H1N1v (proven cases), or an antigen and/or
a positive culture for influenza A (probable cases). The
latter cases were included because virtually no other
seasonal influenza A viruses were circulating in Belgium
during the epidemic period (less than 0.4%, data from
the Belgian National Institute of Public Health). More-
over, specific H1N1v PCR confirmation was no longer
carried out routinely at the end of the epidemic, due to
the high cost of this testing and the limited number of
cases after December 2009.
Data collection and definitions
Data were collected retrospectively from patients’ medi-
cal files using a standardized questionnaire.
A pre-existing co-morbidity was defined as a chronic
condition requiring long term medication or medical
follow up. Co-morbidities were listed based upon CDC
H1N1 flu guidelines http://www.CDC.gov/h1n1flu.htm
and other recent publications [8]. Co-morbidities were
not mutually exclusive, so that a child could participate
in several categories.
Fever was defined as a central temperature above 38°
Celsius.
Nosocomial infection was defined as a proven or
probable case occurring after more than 48 hours of
hospitalization.
Microbiological testing
Respiratory samples collection included nasopharyngeal
aspirates, nasopharyngeal flocked swabs (Copan Diag-
nostics, Corona, CA), throat flocked swabs (Copan Diag-
nostics, Corona, CA) and sputum.
Antigen testing was assessed by immunochromato-
graphic rapid antigen detection (RAT) in three of the
four centers or also by direct immunofluorescence
(DIF) technique (Argene SA, Verniolle, France) in one
of them. Both DIF and immunochromatography use
highly sensitive monoclonal antibodies directed against
either influenza A or B nucleoprotein antigens [18].
RAT was performed using two different testing: the
Coris Influ-A&B Respi-Strip (Coris Bioconcept, Gem-
bloux, Belgium) and the Binax Now influenza A & B
(Binax Inc., Inverness medical, Maine, USA). Direct
antigen testing was unavailable in the fourth participat-
ing hospital, representing 26% of our cohort of
patients.
Viral culture was performed on the three following
cell lines: Vero, MRC-5 and LLC-MK2 in two centers;
and MDCK, Hep-2, MRC-5 and LLC-MK2 in a third
hospital, as described elsewhere [19]. In the fourth cen-
ter which used DIF and RAT for antigen detection,
respiratory samples were not cultured as antigen detec-
tion was followed directly by real-time PCR. (This cen-
ter represented 22% of the cohort).
Biomolecular testing consisted, for three of the four
centers, firstly in detection of influenza A virus by a
home-made real-time RT-PCR (RT-PCR InflA) targeting
the matrixprotein-coding gene and consequently by spe-
cific detection of the circulating pandemic variant using
two monoplex real-time RT-PCR assays as described in
the Centers of Disease Control (CDC) protocol: the SW
InfA PCR (SWINE) and the SW H1 PCR (RT-PCR A/
H1N1) [20]. In the fourth center (26% of samples), a
commercial available PCR kit was used directly for
detecting the pandemic strain: “Swine influenza virus
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Liège, Belgium).
Statistical analysis
Statistical analyses were performed using Graph Pad
Prism Software, Inc, 2003, San Diego, USA. Chi square
or Fisher’s exact tests were used to compare non contin-
uous variables and Mann Whitney u- test was used to
compare continuous variables. A two-tailed p-value less
than 0.05 was considered as statistically significant.
Ethical Consideration
Approval of the Medical Ethics Committees of the four
hospitals was obtained before starting the study. A code
number was attributed to each child so that data col-
lected remained strictly confidential.
Results
Epidemiological Data
During the epidemic period, an excess of 18% (+10486)
of pediatric outpatients and emergency department visits
was registered, as compared with the mean measured
over the 3 previous years during the same months. Fig-
ure 1 represents the evolution of H1N1v 2009 pediatric
hospitalized cases over time in the four hospitals, with
peak of the epidemic observed between the end of Octo-
ber and the beginning of November 2009. 215 children
were hospitalized with proven or probable influenza A/
H1N1v infection; representing 2% of the total hospitals’
admissions registered during the whole study period but
6% (191/3144) of those during the four weeks of the
peak of the epidemic. Additionally, the PICU occupation
rate by influenza A/H1N1v infected children was 3.5%
over the whole study period and reached 8% during the
peak of the epidemic.
Among our cohort of 215 children, 57% were male.
The median age of the patients was 31 months (range: <
1 to 208 months), with 19% of the children having less
t h a n3m o n t h so fa g e( F i g u r e2 ) .A ss h o w ni nT a b l e1 ,
101/215 (47%) children presented with one or more
underlying co-morbid condition, principally chronic
lung diseases and neurological disorders. The median
age of patients presenting co-morbidities was signifi-
cantly higher than of those without (50 versus 14
months, p < 0.0001).
Clinical Presentation and Diagnosis
The major clinical features, reasons for hospitalization
and blood diagnostic results are summarized in Table 2.
T h em e d i a nd u r a t i o no fs y m p t o m sb e f o r ea d m i s s i o n
was 2 days (IQR: 1-4 d). Presentation on admission con-
sisted mainly in febrile respiratory illness, with a high
prevalence of gastrointestinal symptoms, independently
of age groups (Table 3). Moreover, 21 children (10%)
presented initially with neurological manifestations.
Based upon initial clinical presentation, diagnosis of
influenza A/H1N1v infection was suggested by clinicians
in 56% of children (Table 2). 74/215 (34%) children had
chest X-ray confirmed pneumonia, associated in 6%
with pleural effusion. Three patients had confirmed bac-
terial superinfection with Streptococcus pneumoniae
(positive blood cultures). For five patients (2%), the
influenza infection was hospital acquired.
As shown in Table 3, children aged less than 3
months old had a significantly lower rate of pneumonia
and tended to have less neurological manifestations than
older ones. For this age group, the main reason for hos-
pitalization was surveillance of acute fever without
focus. Initial clinical presentation was globally similar
between patients with and without chronic co-morbid-
ities, except for hypoxemia (Table 3).
Blood inflammatory profile on admission was vari-
able, with 13% of the children presenting with leukope-
nia and 6% with thrombocytopenia (Table 2).
Respiratory samples collected to diagnose influenza A/
H1N1v infection were nasopharyngeal aspirates and
nasopharyngeal swabs in 58% and 39% of the patients,
Figure 1 Epidemic curve of children hospitalized with influenza
A/H1N1v infection. Brussels, July 2009-January 2010.
Figure 2 Age distribution of the 215 hospitalized children with
influenza A/H1N1v infection. Brussels, July 2009-January 2010.
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standard), the sensitivity of antigen by RAT was low,
being only 29% (10/34) and 57% (47/83) using Coris
RespiStrip and Binax Now testing, respectively (data
not calculated for DIF method, as only performed on
11 samples). The sensitivity of culture was quite better
at 76% (107/141).
Treatments
Among the 215 children, only 51 (24%) received osel-
tamivir (doses according to weight and age [21]). For a
large majority of them (37/47, data unavailable for
three children), antiviral therapy was started directly
on admission and was continued for five days (35/41,
data unavailable for 9 patients). Rate of oseltamivir
prescription reached 42% and 71% for children having
pneumonia and for those requiring PICU admission,
respectively. No significant related adverse events were
reported. Oseltamivir was significantly more frequently
prescribed among children older than 2 years com-
pared to younger ones (Table 4) and among children
with underlying disease (39/101 [39%]) versus 12/114
[11%], p < 0.0001). Additionally, 57% (123/215) of the
patients were treated with antibiotics, for a median
duration of seven days. In only 17 of them (14%), anti-
biotic therapy was discontinued after obtaining confir-
mation of influenza A/H1N1v infection (data
unavailable for seven cases). Among children treated
by antibiotics, 54% had a diagnosis of pneumonia.
Finally, antibiotics were similarly used in all patients’
a g eg r o u p s( T a b l e4 ) .
Intensive Care
21/215 patients (10%) had to be admitted to PICU,
mainly within 24 hours of admission. Among them, the
prevalence of co-morbidity (62%) tended to be higher
than observed among ward patients, with a predomi-
nance of neurological disorders (Table 1). The median
age of PICU children was 75 months (IQR 47-130).
PICU admissions were significantly more frequent in
children above two years of age (Table 4) and no infant
less than three months old required intensive care.
The major reason for PICU admission was respiratory
failure subsequent to pneumonia (Table 3). Seven patients
(3% of the global cohort) presented an Acute Respiratory
Distress Syndrome (ARDS) and three had pleural effusion.
Two patients were admitted for surveillance because of
severe underlying disease. None of the 21 children pre-
sented seizures or signs of viral encephalitis (Table 3). The
median duration of PICU stay was four days and ranged
from 1 to 90 days. 13/21 (59%) children received respira-
tory support with non invasive ventilation (NIV); eight
(38%) required mechanical invasive ventilation for a med-
ian duration of six days (range 1 to 45). One previously
healthy child presenting with severe ARDS followed by
cardiac-respiratory arrest had to undergo Extra Corporeal
Membrane Oxygenation (ECMO) support during 12 days,
but survived with mild respiratory sequelae.
Clinical Outcome
The median duration of hospitalization was three days
(IQR: 2-6 d). This result was unaffected by the patients’
age (Table 4).
Table 1 Chronic co-morbid conditions in children hospitalized with influenza A/H1N1v infection in Brussels
Global cohort Ward patients PICU patients
N = 215 N = 194 N = 21
N of Patients with ≥ 1 co-morbidity (%) 101 (47) 88 (45) 13 (62) p = 0.1
Distribution of co-morbidities n (%) n (%) n (%)
Chronic lung disease 32 (15) 30 (15) 2 (10)
Asthma 18 (8) 18 (9)
Neurological disease 31 (14) 26 (13) 5 (24)
History of prematurity 21 (10) 21 (11) none
median GA* (weeks) 33 W
Hemato-oncology 19 (9) 17 (9) 2 (10)
HSCT** 2 (1) 2 (1)
Sickle-cell disease 8 (4) 7 (4) 1 (5)
Congenital heart disease 14 (7) 12 (6) 2 (10)
surgically corrected 6 (3)
Malnutrition 12 (6) 12 (6) none
Metabolic disease 3 (1) 3 (2) none
Diabetes 2 (1) 1 (< 1) 1 (5)
Renal disease 3 (1) 2 (1) 1 (5)
Solid organ transplant 2 (1) 1 (< 1) 1 (5)
Legend:* Gestational age,** Hematopoietic cell transplantation recipients
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N = 215 N = 201¹
Presentation on admission n (%) Blood test values on admission
H1N1 suspicion 121 (56) Median Leukocyte count/mm3 9050
(IQR*) (6070-12060)
Symptoms/signs N (%) of patients with leukopenia ≤5000/mm
3 27 (13)
Fever 188 (88) Median Lymphocyte count/mm3 2147
Cough 129 (60) (IQR) (1249-3632)
Rhinorrhea 105 (49) N (%) of patients with lymphopenia ≤1000/mm
3 33 (16)
Loss of appetite 58 (27)
Vomiting 54 (25) Median PMN** count/mm
3 4378
Asthenia 49 (23) (IQR) (2667-8179)
Diarrhea 39 (18) N (%) of patients with neutropenia ≤1500/mm
3 21 (10)
Convulsion 21 (10)
Dehydration 11 (5) Median Platelet count/mm3 297500
Headache 11 (5) (IQR) (211000-381500)
Myalgia 10 (5) N (%) of patients with thrombocytopenia ≤150.10
3/mm
3 12 (6)
Rash 7 (3)
Abdominal pain 5 (2) Median CRP*** (mg/dL) 1.55
Thoracic pain 5 (2) (IQR) (< 0.5-5.15)
range < 0.5-44.7
N (%) of patients with CRP > 5 mg/dl 51 (25)
Reason for hospitalization n (%) Respiratory complications n (%)
Altered general status 89 (41) Hypoxemia
2 58 (27)
Respiratory distress 78 (36) median oxygen saturation
3 90%
(85-92 IQR)
IV treatment 67 (31) median duration of oxygen supplementation 2.5 days
Underlying disease 53 (25) Lobar pneumonia 57 (27)
O2 requirement 52 (24) Diffuse pneumonia 18 (8)
< 3 months old 41 (19) Pleural effusion 13 (6)
Seizure/malaise 22 (10) Apnea 3 (1)
Anorexia/vomiting 14 (7) Pneumothorax 2 (1)
« Sepsis-like » illness 6 (3)
Parental request/non compliance 2 (1)
Legend: *IQR = interquartile range; **PMN = polymorphonuclear leukocytes; ***CRP = C-reactive protein; 1 201 children with blood results available on
admission; 2 defined as Hb oxygen saturation less than 94%; 3 transcutaneous saturation
Table 3 Clinical features of influenza A/H1N1v infection according to age, co-morbidity and PICU admission among
hospitalized children
Clinical presentation
Pneumonia Hypoxemia Seizures GI* manifestations
n (%) n (%) n (%) n (%)
Global cohort (N = 215) 74 (34) 58 (27) 21 (10) 78 (36)
Age groups (months)
< 3 months (n = 41) 7 (17) p = 0.03 4 (10) p = 0.01 1 (2) p = 0.19 13 (32) p = 0.74
3-24 months (n = 59) 23 (39) 15 (25) 6 (10) 21 (36)
> 24 months (n = 115) 44 (38) 39 (34) 14 (12) 44 (38)
Co-morbidity
yes (n = 101) 32 (32) p = 0.4 34 (34) p = 0.03 10 (10) p = 0.95 33 (33) p = 0.3
no (n = 114) 42 (37) 24 (21) 11 (10) 45 (39)
PICU admission
yes (n = 21) 15 (71) p < 0.001 18 (86) p < 0.001 0 (0) p = 0.2 5 (24) p = 0.2
no (n = 194) 59 (30) 40 (21) 21 (11) 73 (38)
Legend:*GI = gastrointestinal manifestations, including nausea, vomiting and/or diarrhea
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(5/215). The five deaths were directly attributable to
influenza A/H1N1v with or without bacterial superinfec-
tion and occurred in children with co-morbidities who
would otherwise have died from their underlying dis-
ease. These underlying diseases consisted in neurological
disorders from various etiologies (extensive central ner-
vous system glioma, polymalformative syndrome, Hurler
syndrome, cerebral palsy and severe encephalopathy
with pontocerebellar hypoplasy). For all of them, severe
pneumonia was notified, associated for three children
with ARDS. All deaths concerned children aged more
than two years old (Table 4). Four of the five children
had received oseltamivir within 48 hours of clinical
symptoms.
Three additional patients (1%) were cured from influ-
enza A/H1N1v infection but still suffered from sequelae
at the end of the study (two had bronchiectasis with
emphysema and one a pulmonary restrictive syndrome
needing tracheotomy and NIV support at home).
Discussion
Even though consequences were less dramatic than initi-
ally feared, the 2009 influenza A/H1N1v pandemic has
caused a significant burden of disease worldwide, espe-
cially in the pediatric population [6-8]. Higher attack
rate was observed among children, causing important
overload in outpatient and emergency departments [11]
as well as in PICU [22]. Unfortunately, our study was
not designed to assess the epidemiological impact of
influenza A/H1N1v infection over the whole pediatric
population of Brussels. Moreover, by selecting only
laboratory confirmed infections, we underestimated the
number of hospitalized cases, especially since diagnosis
confirmation by PCR was no more routinely performed
at the end of the epidemic. However, we were able to
notice an important pediatric burden of disease in Brus-
sels, as illustrated by an increased rate of outpatients
visits of 18% during the epidemic period compared to
the three previous years and a high rate of PICU occu-
pation by influenza A/H1N1v infected patients (8% dur-
ing the peak of epidemic). It would have been of
interest to compare the rate of hospitalization related to
H1N1 with those registered for seasonal flu during the 3
previous years but these data were unfortunately not
available.
This study offers a comprehensive description of influ-
enza A/H1N1v pattern of infection among Belgian hos-
pitalized children, in the light of recent publications
from other continents. Consistently with these reports
[9-12,23,24], co-morbidities were highly prevalent
among influenza A/H1N1v infected hospitalized chil-
dren (47%). The co-morbidities were not different from
those observed during seasonal flu. As described by
others [7,9,22], the presence of at least one co-morbidity
was significantly more frequent in children of more than
two years of age and constituted a risk factor for sever-
ity of disease, in terms of PICU admissions and case-
fatality rate. Furthermore, influenza A/H1N1v illness
course differed according to patients’ age groups.
Indeed, children less than two years of age (46% of the
cohort), and especially those less than three months,
presented milder patterns of infection and were often
hospitalized only for observation of fever without focus.
86% of PICU admissions and all deaths occurred in chil-
dren over two years of age (with 80% of deaths among
children > five years old). Although this issue is conflict-
ing in the medical literature [7,10], similar findings have
been reported in a large series by investigators from the
CDC [25]. This observation differs from what is seen
during seasonal flu, where young children and especially
infants presented a higher mortality-rate compared to
older ones [26,27]. Nevertheless, during this pandemic
wave as well as during previous flu seasons, the highest
rate of hospitalization was generally reported among
young age groups [8,9,11,24]. This was particularly true
in our series, as reflected by a median of age of 31
months, which was even younger than among American
and Israeli hospitalized children (median age ranging
from four to six years) [9,10]. If unexplained by the
severity of infection, this finding probably illustrates dif-
ferences in clinical practices and hospitalization policies.
In Belgium, the National Healthcare System renders the
access to inpatients pediatric facilities easy, so that hos-
pitalization of infants presenting with fever without
focus, especially those younger than 3 months of age, is
largely recommended and not restricted to the most
severe cases as in other countries [28,29].
Although we focused on hospitalized cases, influenza
A/H1N1v episodes were mainly self-limited, consisting
Table 4 Co-morbidity, treatment and outcome according
to age in children hospitalized with influenza A/H1N1v
infection
Children’s age groups
< 2 years ≥ 2 years
N = 100
(%)
N = 115
(%)
Rate of co-morbidity 31 (31) 70 (61) p<
0.0001
Treatment
Oseltamivir 11 (11) 40 (35) p = 0.001
Antibiotics 58 (58) 65 (56)
PICU admissions 3 (3) 18 (16) p = 0.002
Invasive ventilation 2 (2) 6 (5)
Median duration of
hospitalization (d)
3 4 p = 0.13
Death 0 (0) 5 (4) p = 0.06
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of hospitalization (median 3 days) with or without oxy-
gen supplementation. Initial clinical features did not dif-
fer from seasonal flu [30], except for the higher
proportion of children presenting with gastrointestinal
manifestations, as described in previous studies
[12,23,24]. This involvement of the gastrointestinal tract
could be subsequent to a high rate of influenza A/
H1N1v virus replication [31]. Neurological manifesta-
tions were also frequent (10% of children) but in con-
trast with other reports [9,22] were not correlated with
PICU admission or fatality. Finally, more than one third
of the whole cohort and 71% of PICU patients had
pneumonia confirmed on chest X-rays. Even though
only 3 (1%) children had evidence of bacteremia (all due
to S. pneumoniae), it seems very likely that a significant
proportion of pneumonia, especially those with lobar
infiltrates, were associated with bacterial super-infec-
tions. According to some series, bacterial super-infec-
tions after influenza A/H1N1v episodes were found in
about 4% of hospitalized children [11,12,23] but reached
20 to 38% among fatal cases [7,25,32]. Considering the
low rate of positive blood cultures (BC) in pediatric bac-
terial community-acquired pneumonia (2.5 to 5%)
[33,34], these published rates as well as our data likely
constitute an under-estimation, as bacterial pneumonia
diagnosis relied on positive cultures from sterile sites or
autopsies and as part of children had received antibiotics
prior to microbiological documentation. Finally, among
our whole cohort, no necrotizing pneumonia, empyema
or sepsis due to S. aureus or group A Streptococcus
were reported, even though those pathogens are fre-
quently involved in other series [9,25].
Surprisingly, a majority of children were treated by
antibiotics, even after the diagnosis of influenza A/
H1N1v infection was obtained. As mentioned above, con-
firming bacterial pulmonary super-infection after influ-
enza illness is challenging and diagnostic relies more on
clinical presumption and unspecific blood results [35].
H o w e v e r ,t h i sc o u l do n l yp a r t l ye x p l a i nt h eh i g hr a t eo f
antibiotics use, as only 54% of those children treated by
antibiotics presented pulmonary infiltrates. Rate of anti-
biotics prescriptions was uniform among all age groups
and was also high in other pediatric studies [10-12]. The
exact reasons sustaining this practice remain unknown
but should be worth to investigate in further prospective
studies. Contrastingly, our study showed a particularly
low percentage of oseltamivir prescriptions. Indeed, only
24% of the children were treated compared with 45 to
84% in other similar studies [8,9,11,12]. In our four cen-
ters, the use of oseltamivir was significantly higher in
children above 2 years of age and/or suffering from co-
morbidities. This more “watch and wait” practice was in
line with the restrictive national recommendations issued
for oseltamivir pediatric use during the 2009 pandemic
wave, which suggested cautious prescription under one
year of age, regarding the absence of safety data among
infants [16]. Moreover, in Belgium, prescription of anti-
viral drugs during seasonal flu is very limited and kept
for management of severe diseases or immuno-compro-
mised patients [36]. Obviously, the limitations associated
with the retrospective design do not allow us to conclude
on treatment efficacy. It is however interesting to note
that, although oseltamivir was scarcely used, fatality rate
and PICU admissions were comparable to the other
above-mentioned reports [9,10,12].
In Argentina [8], the case-fatality rate of influenza A/
H1N1v infected children was 5%, with a global pediatric
mortality rate 10 times greater compared to previous flu
seasons. National surveys in the United Kingdom [7] and
U.S [23] reported also a higher influenza related mortality
rate during the pandemic influenza A/H1N1v than
observed with seasonal flu. However, consequences in the
Northern hemisphere were less dramatic than anticipated.
Studies from these countries reported case-fatality rate
among hospitalized children ranging from 0.6 to 3% [9-12],
s i m i l a rt oo u rf i n d i n g s( 2 % ) .A sp r e v i o u s l yh y p o t h e s i z e d
[10], these North/South differences in patients’ outcome
could partly be explained by an easier access to the health
care system in Europe, Israel and North America. In Israel
[10], as well as in our series, the median duration of symp-
toms before hospitalization was only 2 days compared to 4
days in Argentina [8]. On another hand, 2 patterns of influ-
enza A/H1N1v related deaths have been described [7]:
those occurring after several days of hospitalization in
chronically ill patients (80%), in contrast to those observed
after acute evolution of viral infection in previously healthy
children (20%). Despite a small number of cases, a similar
profile seemed to happen in our series, as the five children
who died suffered from chronic neurological disorders and
one previously healthy child presented a fulminant viral
infection causing cardio-respiratory arrest and requiring
nine days of ECMO support to be cured.
Conclusion
Although influenza A/H1N1v infections were globally
self-limited, pediatric burden of disease was significant.
Children of more than 2 years old and/or suffering from
chronic co-morbidities were shown at higher risk of
severe infection. Compared to other countries experien-
cing different health care systems, our Belgian cohort
was younger and received less frequently antiviral ther-
apy; disease course and mortality were however similar.
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